First look at The Endocrine Society's Performance-Enhancing Drugs Scientific Statement

Performance-enhancing drugs are synonymous with the names of elite athletes including Alex Rodriguez and Ryan Braun. In reality, major league athletes make up only a fraction of the nation's 3 million performance-enhancing drug users. As thousands of PED users age into their 50s, the long-term health effects are expected to become visible for the first time.

Testosterone expert Dr. Shalender Bhasin will be sharing an exclusive first look at The Endocrine Society's Performance-Enhancing Drugs Scientific Statement in New York Dec. 13. He will counter the misperception that PEDs are largely safe or that any adverse effects can be easily managing by discussing what science has already revealed about serious and even fatal effects of PED use. Journalists who attend will have an opportunity to review an embargoed copy of the statement and interview Dr. Bhasin prior to the statement's upcoming release.

What:
Exclusive Sneak Peak at The Endocrine Society's Embargoed Performance-Enhancing Drugs Scientific Statement

When:
Friday, December 13, 2013
12:30 p.m.

Where:
Grand Hyatt New York
Regency Conference Room, Mezzanine Level
109 East 42nd Street
New York, NY 10017

The press event will take place during The Endocrine Society's Hormones & Health Science Writers Conference. Media are invited to attend this event at no cost, although seating is limited. Breakfast and lunch will be provided by the Society. Registration and program details are posted online at https://www.endocrine.org/sciencewriters.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options